
NexoBrid®

Disruptive Bioactive Therapy for Burn Care



Eschar Removal


Critical First Step in Burn Care



- Prevents infection and sepsis
- Stops deterioration and scarring
- Tissue visible for medical evaluation

Traumatic SOC[1]

Surgical, Non-Selective



- Loss of healthy tissue and blood
- Challenging in delicate areas
- Requires surgical team, operating room

NexoBrid: Rapid, Effective, and Selective







- Sterile mixture of proteolytic enzymes
- Globally approved for eschar removal in adult and pediatric burn patients in 40+ countries
- 18,000+ patients treated to date
- Topical application at patient's bedside
- Minimizes need for surgery and significantly reduces blood loss
- Improves patient outcomes (scar quality and function) Removes eschar within 4 hours
- Enables visual medical assessment
- Commercially available in U.S., EU, JP
- $140M US government support

[1] standard of care